HC Wainwright reaffirmed their buy rating on shares of Stealth BioTherapeutics (NASDAQ:MITO) in a report published on Friday, Stock Target Advisor reports. HC Wainwright currently has a $21.00 target price on the stock.
Other analysts have also issued reports about the company. Zacks Investment Research raised Stealth BioTherapeutics from a sell rating to a hold rating in a research note on Tuesday, November 12th. Nomura set a $28.00 price target on Stealth BioTherapeutics and gave the stock a buy rating in a research note on Friday, October 18th. Cantor Fitzgerald began coverage on Stealth BioTherapeutics in a research note on Friday, September 27th. They issued an overweight rating and a $18.00 price target on the stock. Finally, Jefferies Financial Group set a $9.00 price objective on Stealth BioTherapeutics and gave the company a hold rating in a research note on Tuesday, October 15th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $21.86.
NASDAQ:MITO traded down $1.49 during mid-day trading on Friday, reaching $7.15. The company’s stock had a trading volume of 23,700 shares, compared to its average volume of 22,193. The company’s fifty day simple moving average is $6.71 and its two-hundred day simple moving average is $10.26. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.13 and a quick ratio of 2.13. Stealth BioTherapeutics has a twelve month low of $4.97 and a twelve month high of $20.99. The stock has a market cap of $270.78 million and a P/E ratio of -5.07.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its quarterly earnings results on Thursday, November 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Sell-side analysts expect that Stealth BioTherapeutics will post -0.2 EPS for the current fiscal year.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Featured Story: What is the role of the G-20?
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.